Within one day, a number of pharmaceutical companies announced that a new class of drug was approved for listing

The industry said that the country is supporting the development of domestic innovative drugs through the baton of medical insurance, and gradually guiding the development of China's pharmaceutical industry from large to strong, from imitation to innovation
.
For example, in the 2021 medical insurance catalogue adjustment and national talks, the characteristics of innovative drugs are very obvious, which highlights that China's pharmaceutical market is at a critical turning point
.
The author has learned that with the rapid development of innovative drugs, news of new drugs being launched or approved for clinical trials has been coming
.
Recently, a number of pharmaceutical companies have been approved for listing of Class 1 new drugs
.
For example, on December 16, Hansen Pharmaceutical Group Co.
, Ltd.
announced that its subsidiary, Hansen Pharmaceuticals, independently developed a category 1 innovative drug Ametinib mesylate (trade name: Amelox), which is used for epidermal growth factor receptors.
Indications for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with exon 19 deletion or exon 21 (L858R) substitution mutation positive in EGFR Drug Registration Approval Document
.
Ameile is a Class 1 innovative drug independently developed by Hansen Pharmaceuticals, and it is also the original third-generation EGFR-TKI in China
.
It is reported that this is the second indication approved by Amelo
.
Hansen Pharmaceuticals stated that it will continue to pay attention to unmet clinical needs, accelerate the pace of scientific and technological innovation, and strive to launch more new and good drugs as soon as possible, and effectively shoulder the corporate mission of "making national medicines better and creating stronger China".
To meet people’s access to medicines and their pursuit of a healthy and beautiful life, and to help implement the "Healthy China 2030" strategy
.
On the same day, on December 16, Zai Lab also announced that the State Drug Administration (SFDA) had approved the company's application for the company's Class 1 new drug omacycline tosylate
.
It is reported that omacycline tosylate is a new type of antibiotic, available in oral and intravenous infusion formulations, approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI)
.
Omacycline tosylate has been approved by the State Food and Drug Administration as a Class 1 new drug and is being produced in China
.
A person from Zai Lab stated that the approval of Omacycline tosylate by the State Food and Drug Administration has brought a new and important treatment option to millions of CABP and ABSSSI patients in China
.
In addition to a number of pharmaceutical companies that have been approved for listing of Class 1 new drugs, many pharmaceutical companies have announced that their Class 1 new drugs have been approved for clinical trials
.
For example, on the evening of December 16, Tonghua Dongbao disclosed that its subsidiary Dongbao Zixing received on December 15 the approval for the drug clinical trial of a new class 1 drug URAT1 inhibitor (THDBH130 tablet) issued by the Drug Evaluation Center of the State Drug Administration Notice, the acceptance number is CXHL2101548, CXHL2101549
.
Data show that HDBH130 tablets are a drug targeting URAT1 to treat gout and hyperuricemia.
The approved indications for THDBH130 tablets this time are hyperuricemia and gout
.
At noon on December 13, Enhua Pharmaceuticals announced that the company had recently received the "Drug Clinical Trial Approval Notice" for the Class 1 chemical drug NH600001 emulsion injection approved and issued by the National Medical Products Administration, and will start clinical trials in the near future
.
It is reported that the molecular structure of NH600001 is similar to etomidate, and it is planned to be developed into a new class 1 drug for short-acting intravenous anesthesia with obvious advantages over etomidate
.
In addition, Better Pharmaceuticals recently announced that its self-developed Class 1 new drug BT-101094 capsules have been approved for clinical trials
.
Namely, Better Pharmaceuticals and its innovative drug research and development institution-Chengdu Haiborui Pharmaceutical Co.
, Ltd.
received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, approving the company's independent research and development of Class 1 chemical innovative drugs "BT-101094 Capsule" carries out clinical trials of advanced malignant solid tumors
.
Nowadays, driven by national policies, the domestic innovative drug market has ushered in a golden development cycle
.
Many pharmaceutical companies are also actively seizing opportunities to promote the development of innovative drugs
.
For example, Better Pharmaceuticals said that with its strong R&D strength, the company has successively made important breakthroughs in the research and development of innovative drugs, and the innovative core will continue to inject new momentum into the company’s sustained and rapid development.

.
Tonghua Dongbao stated that the company firmly seized the historical opportunity of encouraging innovative drugs by the state, and based on the research and development of drugs in the field of diabetes and other important endocrine fields, it entered the field of innovative drugs and further enriched its R&D pipeline
.